ARE vaccines coming in from the cold? That’s the question this week after Eli Lilly splashed out almost $4 billion on three vaccine biotechs, two of which are in the early stage of clinical development. All are developing jabs for or related to infectious diseases. Why’s this a big deal? Because everyone knows that […]
Progress for our clients in the clinic this week, with Mestag Therapeutics dosing the first patient in their STARLYS clinical trial and STORM Therapeutics to present data on its dose escalation study at ASCO later this month. More good news, as Hansa Biopharma entered a multi-million-Euro licensing agreement with SERB S.A. Bring on the bank […]
Riding the wave of BioEquity, it has been another busy week for Optimum’s clients. Hansa Biopharma, Poolbeg Pharma and Resolution Therapeutics are all taking to the stage across Europe and the US. Optimum’s own Stephen Adams will be chairing a panel at LSX Nordic next week after yet another fascinating Hot Topic – this time […]
Here’s a novel thought: could the science that has enabled us to develop obesity drugs, be repurposed to help people put on weight? Now, the vast majority of us don’t, of course, need to put on weight. But some people do – notably many individuals with eating disorders such as anorexia nervosa. In a ‘Perspectives’ paper recently published in the New England Journal of Medicine, and an […]
Weekly roundup: May the ‘4th’ be with you! May the ‘4th’ be with you! (Sorry – we couldn’t help ourselves.) The force of innovation was strong across the life sciences sector this week. The Optimum team joined leaders from across the industry at this year’s BioEquity Europe conference in Prague, where discussions reflected the sector’s […]
